WilmerHale Advises Apellis Pharmaceuticals in $120M Collaboration With SFJ Pharmaceuticals

WilmerHale Advises Apellis Pharmaceuticals in $120M Collaboration With SFJ Pharmaceuticals

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.

On February 28, 2019, Apellis Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, announced a novel, risk-sharing collaboration to support the development of APL-2 in hematologic indications with SFJ Pharmaceuticals, a global drug development company backed by Blackstone Life Sciences and Abingworth. Apellis is expected to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement.

Steve Barrett and Stuart Falber led the WilmerHale team representing Apellis, along with John Sigel and Byron Crowe.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel